Drug intelligence / Profile preview

Lipidots

Development stage: Preclinical
Lead developer: CEA-Leti
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

Lipidots is a proprietary lipid-based nanoemulsion platform developed by CEA-Leti for the encapsulation and delivery of lipophilic drugs and imaging agents. These nanoparticles consist of a lipid core (typically a mixture of soybean oil and wax) stabilized by a surfactant shell (such as lecithin). Lipidots are designed to improve the solubility, stability, and biodistribution of hydrophobic compounds, such as the photosensitizer m-tetrahydroxyphenylchlorin (mTHPC). In the context of photodynamic therapy (PDT), Lipidots facilitate the accumulation of photosensitizers in tumor tissues, thereby enhancing therapeutic efficacy while minimizing side effects like skin photosensitivity.

Other names: Lipid nanoemulsions

Targets

Cellular and endosomal lipid membranes

Beyond the preview

Go deeper on Lipidots.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lipidots.

Explore the full profile